NASDAQ:PSTI Pluristem Therapeutics (PSTI) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free PSTI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.00▼$1.5852-Week Range N/AVolume2,128 shsAverage Volume715,259 shsMarket Capitalization$32.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pluristem Therapeutics alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Pluristem Therapeutics Stock (NASDAQ:PSTI)Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.Read More Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> PSTI Stock News HeadlinesAugust 18, 2023 | seekingalpha.comNBRVF Nabriva Therapeutics plcJuly 25, 2022 | finance.yahoo.comPluri CEO Issues Shareholder UpdateMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.July 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 14, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 13, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | markets.businessinsider.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.July 13, 2022 | finance.yahoo.comPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryMay 10, 2022 | apnews.comPluristem: Fiscal Q3 Earnings SnapshotMarch 28, 2022 | finance.yahoo.comPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipMarch 23, 2022 | seekingalpha.comPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialMarch 23, 2022 | finance.yahoo.comPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsMarch 21, 2022 | nasdaq.comPluristem Therapeutics, Inc. Common Stock (PSTI)March 8, 2022 | finance.yahoo.comPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureFebruary 24, 2022 | finance.yahoo.comPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformJanuary 12, 2022 | marketwatch.comThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?January 10, 2022 | msn.comIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatJanuary 10, 2022 | finance.yahoo.comBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food PlatformJanuary 10, 2022 | nasdaq.comPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative MeatJanuary 10, 2022 | seekingalpha.comPluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food productsJanuary 10, 2022 | finance.yahoo.comBiotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food PlatformDecember 30, 2021 | nasdaq.comPluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market MoverDecember 29, 2021 | marketwatch.comPluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTIDecember 28, 2021 | finance.yahoo.comPluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDSDecember 27, 2021 | nasdaq.comPluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy EndpointSee More Headlines Receive PSTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PSTI CUSIPN/A CIK1158780 Webwww.pluristem.com Phone972747107171Fax972-74-710-8787Employees153Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,870,000.00 Net MarginsN/A Pretax Margin-20,024.79% Return on Equity-100.63% Return on Assets-55.46% Debt Debt-to-Equity Ratio0.57 Current Ratio8.22 Quick Ratio8.22 Sales & Book Value Annual Sales$20,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / BookN/AMiscellaneous Outstanding Shares32,348,000Free Float30,601,000Market Cap$32.35 million OptionableOptionable Beta1.91 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yaacov Yanay (Age 51)Pres, CEO & Director Comp: $612.6kMs. Chen Franco-Yehuda (Age 38)CFO, Treasurer & Sec. Comp: $330.3kMr. Lior RavivChief Technology OfficerMs. Efrat Livne-HadassVP of HRDr. Nitsan Halevy M.D.Chief Medical OfficerMr. Nimrod Bar ZviChief Commercial OfficerMore ExecutivesKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLIMiNK TherapeuticsNASDAQ:INKTCortexymeNASDAQ:CRTXGamida CellNASDAQ:GMDASurrozenNASDAQ:SRZNView All Competitors PSTI Stock Analysis - Frequently Asked Questions How were Pluristem Therapeutics' earnings last quarter? Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. When did Pluristem Therapeutics' stock split? Pluristem Therapeutics's stock reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Pluristem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD). This page (NASDAQ:PSTI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.